![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://www.biospace.com/article/gilead-sciences-fights-back-against-hiv-drug-fraud/
https://www.fiercepharma.com/marketing/gilead-s-converting-truvada-prep-users-to-descovy-faster-than-expected-analyst
https://www.nytimes.com/2019/11/08/health/hiv-prevention-truvada-patents.html
https://www.fiercepharma.com/pharma/gilead-elevates-m-a-architect-dickinson-to-cfo-could-more-deals-be-next
https://www.fiercepharma.com/marketing/abbvie-gilead-and-allergan-three-peat-top-pharma-tv-spending-for-september-2019-tv
https://www.fiercepharma.com/pharma/us-reps-to-gilead-did-your-donation-free-hiv-prevention-drug-truvada-have-strings-attached
https://www.reuters.com/article/us-health-hiv-prep-screening/hiv-prevention-pill-recommended-for-healthy-people-at-risk-idUSKCN1TC2G3
https://www.fiercepharma.com/pharma/gilead-to-donate-2-4m-bottles-truvada-prep-push-to-drive-down-hiv-rates
https://www.fiercepharma.com/pharma/a-surprise-gilead-s-3b-per-year-truvada-to-face-generics-next-year
https://www.ema.europa.eu/documents/regulatory-procedural-guideline/list-centrally-authorised-products-requiring-notification-change-update-annexes_en-0.pdf
http://www.pharmafile.com/news/516234/aids-charity-lambasts-ethically-challenged-gilead-over-price-hikes
https://www.bloomberg.com/news/articles/2017-05-02/gilead-sciences-falls-as-antiviral-drug-sales-miss-their-mark
http://www.pharmatimes.com/news/scotland_first_uk_nation_to_routinely_offer_hiv_prep_1191181
https://www.pharmacompass.com/pdf/news/truvada-emtricitabine-tenofovir-disoproxil-fumarate-gilead-emory-univ-v-amneal-1494842120.pdf
http://www.bizjournals.com/sanfrancisco/blog/biotech/2015/04/gilead-gild-hiv-aids-taf-tenofovir.html